Preventing IgE-mediated allergies remains a significant challenge in modern healthcare, necessitating innovative strategies to address the underlying immunological mechanisms driving allergic reactions. Harnessing major allergens for prophylactic cell therapy presents a promising avenue for allergy prevention. This approach involves leveraging the immunomodulatory properties of allergenic proteins to induce tolerance and desensitization in susceptible individuals. By utilizing specialized cell subsets, such as regulatory T cells or tolerogenic dendritic cells, engineered to target major allergens, it is possible to orchestrate antigen-specific immune responses that mitigate allergic sensitization and promote immune tolerance. This review explores the rationale behind harnessing major allergens for prophylactic cell therapy, discusses recent advancements in the field and highlights the potential of this strategy as a preventive measure against IgE-mediated allergies.
HTML PDFShare this article
Immunochemistry & Immunopathology received 174 citations as per Google Scholar report
